Prima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321
21 juin 2016 20h31 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 21, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce initial safety data from the first cohort of...
Prima BioMed to Maintain NASDAQ Listing
06 juin 2016 21h23 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock...
Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
12 mai 2016 04h25 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Sydys Licenses Clinical-Stage Immuno-oncology Assets in...
Japanese Patent Grants for IMP321 in Cancer
01 mai 2016 20h00 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - May 1, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 5908210 entitled "Use of Recombinant...
IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal
15 mars 2016 03h40 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Mar 15, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using...
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
04 mars 2016 01h32 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Mar 4, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima," the "Company"), has received notification from the Listing Qualifications Department of The...
Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial
02 mars 2016 01h05 HE
|
Prima BioMed Ltd.
SHANGHAI, CHINA and SYDNEY, AUSTRALIA--(Marketwired - Mar 2, 2016) - Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD)
Highlights
First-Ever Chinese-Manufactured...
US Patent Grants for IMP731 Antibody
27 janv. 2016 18h00 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 27, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number US 9,244,059 entitled "Cytotoxic...
Prima BioMed Initiates Phase I Melanoma Study in Australia
26 janv. 2016 17h50 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 26, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial...
Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
22 déc. 2015 07h00 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 22, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Institutional Review Board Approval Now Obtained at Four Clinical Sites in...